Hanseatic Management Services Inc. Acquires 170 Shares of Natera, Inc. (NASDAQ:NTRA)

Hanseatic Management Services Inc. boosted its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 23.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 891 shares of the medical research company’s stock after buying an additional 170 shares during the period. Hanseatic Management Services Inc.’s holdings in Natera were worth $113,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Natera by 25.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 5,776 shares of the medical research company’s stock worth $528,000 after buying an additional 1,155 shares in the last quarter. Chevy Chase Trust Holdings LLC acquired a new stake in shares of Natera during the first quarter worth $14,467,000. Envestnet Portfolio Solutions Inc. raised its position in Natera by 19.2% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 9,047 shares of the medical research company’s stock valued at $827,000 after buying an additional 1,457 shares during the last quarter. Oppenheimer Asset Management Inc. grew its position in Natera by 28.8% in the first quarter. Oppenheimer Asset Management Inc. now owns 17,586 shares of the medical research company’s stock valued at $1,608,000 after purchasing an additional 3,927 shares in the last quarter. Finally, Lisanti Capital Growth LLC acquired a new stake in shares of Natera in the first quarter valued at about $1,189,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have issued reports on NTRA. The Goldman Sachs Group upped their price objective on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Leerink Partners raised their target price on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. BTIG Research upped their price objective on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Morgan Stanley raised their price objective on Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. Finally, TD Cowen boosted their target price on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $125.69.

Natera Stock Up 2.1 %

Shares of NASDAQ:NTRA opened at $126.97 on Thursday. Natera, Inc. has a 1 year low of $40.61 and a 1 year high of $133.54. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The business’s 50-day moving average is $123.75 and its 200-day moving average is $113.16. The company has a market capitalization of $15.70 billion, a price-to-earnings ratio of -51.82 and a beta of 1.53.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. The company had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. Natera’s quarterly revenue was up 58.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.97) EPS. Equities research analysts predict that Natera, Inc. will post -1.96 earnings per share for the current year.

Insider Activity

In related news, CEO Steven Leonard Chapman sold 5,583 shares of the business’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $118.91, for a total value of $663,874.53. Following the completion of the sale, the chief executive officer now directly owns 200,710 shares of the company’s stock, valued at $23,866,426.10. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Natera news, CEO Steven Leonard Chapman sold 5,583 shares of the firm’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $118.91, for a total value of $663,874.53. Following the transaction, the chief executive officer now directly owns 200,710 shares of the company’s stock, valued at approximately $23,866,426.10. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Solomon Moshkevich sold 256 shares of the business’s stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total transaction of $30,737.92. Following the sale, the insider now directly owns 111,891 shares of the company’s stock, valued at approximately $13,434,752.37. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,164 shares of company stock worth $6,157,291. Company insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.